UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 25, 2018
RTI SURGICAL, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 0-31271 | 59-3466543 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| 11621 Research Circle, Alachua, Florida | 32615 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (386) 418-8888
not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On September 25, 2018, RTI Surgical, Inc. (the “Company”) hired Ryan M. Bartolucci as Vice President, Controller. Prior to joining the Company, Mr. Bartolucci, 36, was employed with Sagent Pharmaceuticals, a generic injectable company, from August 2015 to September 2018. Mr. Bartolucci started his career at PricewaterhouseCoopers LLP, where, during his 11 years at the firm, he served in various assurance roles. Mr. Bartolucci is a certified public accountant.
In connection with Mr. Bartolucci’s hiring, he received a one-time equity grant with a grant date value of $75,000, split equally between restricted stock which will vest in three equal annual installments beginning on the first anniversary of the date of grant and stock options which will vest in five equal annual installments beginning on the first anniversary of the date of grant.
Also, in connection with Mr. Bartolucci’s hiring, Johannes W. Louw, who was previously the Company’s Vice President, Controller, moved into a new management role with the Company as Vice President, Financial Planning & Analysis to lead the Company’s financial planning and analysis function.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RTI SURGICAL, INC. | ||||||||
| Date: September 26, 2018 | By: | /s/ Jonathon M. Singer | ||||||
| Name: | Jonathon M. Singer | |||||||
| Title: | Chief Financial and Administrative Officer, Corporate Secretary | |||||||